Drugs / STC314
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT05000671 | Jul 2021 → Dec 2022 | acute respiratory distress syndrome | Grand Medical Pty Ltd. | Unknown | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT06548854 | Nov 2023 → Nov 2024 overdue | infectious disease with sepsis | Grand Medical Pty Ltd. | Active not recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | STC314 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06548854 ↗ |
| Route | Intravenous | “continuous intravenous infusion” NCT05000671 ↗ |